The finding that LGP2 was required for the increase in NF-κB activity induced by DDX39B loss demonstrates a mechanism by which these RNA helicases may interact to regulate response to therapy and indicate that modulating DDX39B or its interaction with LGP2 represents a strategy to improve the response to cancer chemotherapy. This evidence concerns the gene DHX58 and cancer.